Production process for preparing lipstatin

A production process and statin technology, applied in the directions of microorganisms, microorganism-based methods, biochemical equipment and methods, etc., can solve the problems of low fermentation titer and high production cost, and achieve the effect of increasing fermentation titer and reducing production cost.

Inactive Publication Date: 2013-06-05
GUANGZHOU MEDCAN PHARMATECH
View PDF5 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The technical problem to be solved by the present invention is to overcome the defects of high production cost and low fermentation titer of niborestatin in the prior art, and provide a production process for preparing niborestatin with low production cost and high fermentation titer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Production process for preparing lipstatin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1: See figure 1 , the invention discloses a production process for preparing niborestatin, comprising the following process:

[0024] A. Preparation of fermentation broth culture medium

[0025] The fermentation medium is made of glycerin, soybean powder, lecithin, soybean oil, magnesium sulfate, calcium carbonate and potassium dihydrogen phosphate, and the fermentation medium contains 4.0% of glycerin, 4.5% of soybean powder, and 1.5% of lecithin %, soybean oil 5%, magnesium sulfate 0.05%, calcium carbonate 0.05%, potassium dihydrogen phosphate 0.05%.

[0026] B. Fermentation

[0027] B1. Streptomyces toxin was inoculated in the fermentation broth, and the bacterial concentration of the strain was 15%.

[0028] B2. During the strain fermentation process, the temperature of the fermented liquid is controlled at about 25°C. When fermenting for 60-80 hours, add sterile oxygen carrier in an amount of 0.05g / L, and continue fermenting for 100-120 hours.

[0029] ...

Embodiment 2

[0035] Example 2: See figure 1 , the invention discloses a production process for preparing niborestatin, comprising the following process:

[0036] A. Preparation of fermentation broth culture medium

[0037] The fermentation medium is made of glycerin, soybean powder, lecithin, soybean oil, magnesium sulfate, calcium carbonate and potassium dihydrogen phosphate, and the fermentation medium contains 5.0% of glycerin, 6% of soybean powder, and 2.5% of lecithin %, soybean oil 8%, magnesium sulfate 0.1%, calcium carbonate 0.1%, potassium dihydrogen phosphate 0.1%.

[0038] B. Fermentation

[0039] B1. Streptomyces toxin was inoculated in the fermentation broth, and the bacterial concentration of the strain was 20%.

[0040] B2. During the strain fermentation process, the temperature of the fermentation liquid is controlled at about 25°C. When the fermentation is 60-80 hours, add a sterile oxygen carrier in an amount of 0.1g / L, and continue the fermentation for 100-120 hours. ...

Embodiment 3

[0047] Example 3: See figure 1 , the invention discloses a production process for preparing niborestatin, comprising the following process:

[0048] A. Preparation of fermentation broth culture medium

[0049] The fermentation medium is made of glycerin, soybean powder, lecithin, soybean oil, magnesium sulfate, calcium carbonate and potassium dihydrogen phosphate, and the fermentation medium contains 6.5% of glycerin, 7.5% of soybean powder, and 3.0% of lecithin %, soybean oil 10%, magnesium sulfate 0.2%, calcium carbonate 0.2%, potassium dihydrogen phosphate 0.2%.

[0050] B. Fermentation

[0051] B1. Streptomyces toxin was inoculated in the fermentation broth, and the bacterial concentration of the strain was 25%.

[0052] B2. During the strain fermentation process, the temperature of the fermentation liquid is controlled at about 25°C. When the fermentation is 60-80 hours, add sterile oxygen carrier, the amount added is 0.15g / L, and the fermentation is continued for 100-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a production process for preparing lipstatin. The production process comprises the following process flow: preparing a culture medium of a fermentation solution, fermenting and purifying a fermentation product. The culture medium of the fermentation solution contains 3.5%-7.0% of glycerol, 4.5%-8.0% of soybean flour, 1.0%-3.5% of lecithin, 5%-12% of soybean oil, 0.05-0.2% of magnesium sulfate, 0.05-0.2% of calcium carbonate and 0.05-0.2% of potassium dihydrogen phosphate. According to the production process disclosed by the invention, the soybean flour, the soybean oil, the glycerol and the like are taken as a main nitrogen source and a carbon source of the fermentation culture medium, ultrasonic disruption is performed on cells, oscillating extraction is performed to get a lipstatin crude product, and then recrystallization is performed on the crude product to get a lipstatin pure product. The production process disclosed by the invention has the characteristics of simple process, short production cycle, high extraction rate and low production cost.

Description

technical field [0001] The invention relates to a production process, in particular to a production process of niborestatin. Background technique [0002] Lipstatin is a white oil, mainly used as a chemical intermediate in the production of the new weight-loss drug orlistat. Orlistat is produced from the fermentation product niborestatin by one-step hydrogenation reduction. [0003] Orlistat is a new weight-loss drug with non-systemic effects, good tolerance and effectiveness, and a potent, specific and long-acting lipase inhibitor, mainly through selective inhibition of gastrointestinal tract The activity of pancreatic lipase blocks 30% of dietary fat from being absorbed by the body so as to achieve the purpose of weight loss, and opens up a new way for the drug treatment of obesity. It is the only weight-loss drug approved by the FDA that does not affect appetite. It is currently the only weight-loss drug marketed as a non-central nervous system effect. It is currently t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12P17/02C12R1/465
Inventor 肖文花安鸿江文敏
Owner GUANGZHOU MEDCAN PHARMATECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap